Palbociclib
- Generic Name
- Palbociclib
- Brand Names
- Ibrance
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N7O2
- CAS Number
- 571190-30-2
- Unique Ingredient Identifier
- G9ZF61LE7G
- Background
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
...
- Indication
Palbociclib is indicated in combination with letrozole as initial endocrine-based therapy for the treatment of human epidermal growth factor receptor type 2 (HER2)-negative and hormone receptor(HR)-positive tumors in adult patients with advanced/metastatic breast cancer. It is as well approved in combination with fulvestrant in patients with disease progress...
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer, Refractory, advanced Breast cancer, Refractory, metastatic Breast cancer
- Associated Therapies
- -
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT03128619
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma
- First Posted Date
- 2017-04-12
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 43
- Registration Number
- NCT03110744
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Germany
🇩🇪Universitätsklinikum Essen, Essen, Germany
🇩🇪National Center for Tumor Diseases, Heidelberg, Germany
Biomarker-based Study in R/M SCCHN
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2023-11-03
- Target Recruit Count
- 340
- Registration Number
- NCT03088059
- Locations
- 🇧🇪
CHU Saint-Pierre-Site Porte de Hal, Brussels, Belgium
🇮🇹IRCCS - Fondazione G. Pascale, Napoli, Italy
🇬🇧Oxford University Hospitals NHS Trust - Churchill Hospital, Oxford, United Kingdom
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03065621
- Locations
- 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇧🇪CHU Brugmann, Brussels, Belgium
🇧🇪CHU Saint-Luc, Brussels, Belgium
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
- Conditions
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 93
- Registration Number
- NCT03065387
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 96
- Registration Number
- NCT03065062
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 27
- Registration Number
- NCT03024489
- Locations
- 🇹🇭
Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT03007979
- Locations
- 🇺🇸
University of Nebraska, Lincoln, Nebraska, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03006172
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 496
- Registration Number
- NCT02947685
- Locations
- 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.